Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_65_библиотеки_им_акад_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
12.10.2026
Размер:
4 Мб
Скачать
☆
164
Fontan-associated liver disease (FALD),
118, 119
clinical presentation, 119
histological abnormalities, 120
laboratory results, 119
post-Fontan abdominal imaging, 120
pathophysiology, 119
treatment, 120
Fractionated plasma separation and adsorption
system (FPSA), 96
Fresh frozen plasma (FFP), 46, 99
Fructosemia, 31, 47
Fulminant hepatic failure (FHF), 135
Fulminant liver failure, 27
Fungal prophylaxis, 139
G
Galactosemia, 31, 47
Gestational alloimmune hepatitis, see Fetal
alloimmune hepatitis
Giant cell hepatitis, 48
Giant cell hepatitis with autoimmune
haemolytic anemia, 34
Glucose blood levels, 42
Glutamate, 71
Glutamine
pathophysiology, 70
synthetase, 69
Graft versus host disease
acute graft versus host disease, 137
cGVHd, 137, 138
H
Halothane, 37
Heart and liver, anatomic relationships, 113
Hematological disorders, 39
Hematopoietic stem cell transplantation
(HSCT), 125, 126
children, causes of liver injury in, 136
acute graft versus host disease, 137
chronic graft versus host disease
(cGVHd), 137, 138
infection, 136, 137
metabolic, 138, 139
SOS, 126
clinical presentation and diagnosis
criteria, 127–129
physiopathology, 126
prevention, 129–131
risk factors, 127
treatment, 131–135
Hemodynamic stabilisation, 19
Hemophagocytic lymphohistiocytosis
(HLH), 33, 39
Hemophagocytosis, 33
Hepatalgia, 128
HepatAssist, 100
Hepatic arterial buffer response (HABR), 5
Hepatic artery thrombosis (HAT), 148, 149
Hepatic complications of pediatric cardiac
disease, 117
of acute cardiac insufciency
ischemic hepatitis, 118
Fontan-associated liver disease (FALD),
118, 119
clinical presentation, 119, 120
pathophysiology, 119
treatment, 120
Hepatic dysfunction, 2
Hepatic encephalopathy (HE), 63, 99
characterization of, 70
clinical presentation of, 72
denition of, 69
diagnosis, 73, 74
epidemiology of, 72
monitoring of, 73, 74
outcomes, 76, 77
pathophysiology of
BBB, 70
cerebral autoregulation, 71
cerebral edema, 71
glutamate, 71
glutamine, 70
hyperammonia, 69, 70
prognosis, 73, 74
treatment, 74, 76
Hepatic hydrothorax, 109
Hepatic veno-occlusive disease (VOD), 126
Hepatitis B infection, 33
Hepatitis GVHD, 138
Hepatocellular and cholestatic injury, 18
Hepatocellular injury in the critically ill
child, 19
Hepatopulmonary syndrome (HPS), 12, 106
diagnosis criteria of, 107
denition of, 106
diagnosis of, 107
management of, 107
Hepatorenal syndrome (HRS), 60, 82, 83
clinical phenotypes, 83
denition of, 83
diagnosis of, 84, 86
type, 87
Hepatosplanchnic blood ow, 5
Index
https://t.me/medicina_free
165
Hepatotropic virus, 136
High output cardiac failure, 114
clinical presentation, 114
pathophysiology, 114
treatment, 114, 115
High volume continuous venovenous
hemoltration, 95
High-frequency oscillatory ventilation
(HFOV), 134
Hyperammonemia, 12, 70, 94
Hyperammonia, pathophysiology, 69, 70
Hyperammoniemia, 46
Hyperdynamic cardiac failure, 43
Hyperglycemia, 21
Hyperornithinemia-hyperammoniemia-
homocitrullinuria syndrome, 32
Hyperventilation, 76
Hypoglycemia, 20
Hypovolemia, 40
Hypoxemia, 106, 108
Hypoxic liver injury, 2–4
diagnosis of, 13, 14
I
Idiopathic neonatal cholestasis, 33
Idiosyncratic drug, 36
iHD, 94
Immunosuppression (IS), 153–155
Immunosuppressive drugs, 48
Impaired beta adrenergic signalling, 115
Impaired immune response, 44
Indeterminate hepatitis, 32, 35
Indocyanine green plasma disappearance rate
(ICG-PDR), 17
Infection
hepatotropic virus, 136
sepsis, 136, 137
treatments, 134, 135
Inammation, 4–6
INR, 16
Intermittent hemodialysis (iHD), 94, 95
Intra-abdominal hypertension (IAH), 104, 105
ATT for, 105
causes of, 104
diagnosis, 105
management of, 105
Intra-abdominal pressure (IAP), 105
Intracranial hypertension (ICH), 43, 45
Invasive intracranial pressure (ICP)
monitoring, 73
Iron overload, 138
Ischemia-reperfusion injury, 4
Ischemic hepatitis, 118
Isourane, 37
Isoniazid, 37
K
Kaplan-Meier plot, 146
Kayser-Fleischer ring, 39
King’s College criteria, 49
Kupffer cells, 5, 6
L
Lactic acidosis, 37
Lateral segmental grafts (LLS), 144
Lipopolysaccharides (LPS), 6
Liver dysfunction treatment, 135
Liver brosis, 119
Liver function, 152
Liver injury, 44
Liver Injury Units (LIU) score, 49
Liver stiffness, 18
Liver transplant, 65
Liver transplantation (LT), 63, 107, 135
in children
donor selection, 144–146
outcomes and surgical
complications, 146–149
surgical approaches, 143, 144
extracorporeal therapy as bridge to, 48, 49
post-transplant management, 152
immunosuppression (IS) and
rejection, 153–155
liver function, 152
monitoring potential complications,
152, 153
waiting for transplant, 149
indications, 150
pretransplant evaluation and listing,
150, 151
pre-transplant management and
complications on waiting list,
151, 152
Loss of vasomotor tone, 43
Lung inammation, 104
PARDS management, 104
Lymphocyte-depleting antibodies, 154
M
Macrophagic activation syndrome, 33
Magnetic resonance cholangiopancreatography
(MRCP), 14
Index
https://t.me/medicina_free
166
MELD score, 60
Membrane attack complex (MAC), 33
Metabolic diseases, 31, 32
Midodrine with octreotide, 87
Mitochondrial disorders, 31
Mitochondrial dysfunction, 59
Mitochondrial fatty acid oxidation defects, 31
Model for end-stage liver disease (MELD), 60
Modied Seattle criteria, 127
Molecular absorbent recirculating system
(MARS®), 21, 48, 63, 96, 99
Mucosal atrophy, 7
Multiple organ dysfunction syndrome, 44
Mushrooms intoxication, 38
N
N-acetylcysteine (NAC), 21, 37, 47, 48
Neonatal hemochromatosis, see Fetal
alloimmune hepatitis
Nephrotoxicity, 154
Neutrophil gelatinase-associated lipocaline
(NGAL), 83
Nitisinone, 48
Nitisinone (NTBC), 31
NO, 114
Non-invasive ventilation (NIV), 134
Noradrenaline, 87
O
Octreotide, 107
Oliguric renal failure, 44
Omegaven®, 8
Ornithine transcarbamylase deciency, 32
Oxygen delivery, determinants of, 3
Oxygen therapy, 109
P
Paediatric end-stage liver disease (PELD)
score, 50
Paracetamol, 36, 37
Paracetamol/acetaminophen, 40
Parenteral nutrition associated cholestasis, 138
Parenteral nutrition–associated liver disease
(PNLAD), 7, 8
Pathogen-associated molecular patterns
(PAMPs), 82
Pediatric acute on chronic liver failure
(P-CLIF), 56
Pediatric acute respiratory distress syndrome
(PARDS), 104
management, 104
Pediatric multiple organ dysfunction score
(P-MODS), 2
Pediatric sequential organ failure aassessment
score (pSOFA), 2
Peliosis hepatitis, 34
Penicillin G, 48
Penicillins, 139
Peritoneal dialysis (PD), 94, 95
Phenytoin, 38
Phytosterols, 8
Plasmapheresis, 98, 99
Platelet transfusion, 46
Portal vein thrombosis (PVT), 149
Porto-pulmonary hypertension (POPH), 108
denition of, 108
diagnosis, 108
incidence of, 108
management, 108
treatment and transplant consideration,
108, 109
Positive end-expiratory pressure (PEEP), 104
Prometheus
®
, 96, 99
Protein synthesis, 42
Pulmonary arterial pressure (PAP), 108
Pyrrolizidine alkaloids, 40
Pyruvate kinase deciency, 32
R
Renal failure and uid overload, 44
Renal replacement therapy (RRT), 93, 94
indication, 94
methods, 94
CRRT, 95
iHD, 95
peritoneal dialysis, 95
Renin angiotensin aldosterone system
(RAAS), 82
Rituximab, 48
Rumack-Matthew normogram, 47
S
Schwartz formula, 86
SCr, 86
Secondary sclerosing cholangitis
(SSC-CIP), 11
Secondary sclerosing cholangitis in critically
ill patients (SCC-CIP), 4
Sepsis, 4–6, 44, 136, 137
Sequential Organ Failure Assessment
(SOFA), 61
Index
https://t.me/medicina_free
167
Serum aminotransferase levels, 42
Serum bile acids levels, 16, 17
Serum creatinine (SCr) criteria, 83
Sevourane, 37
Silybin dihemisuccinate, 48
Single-pass albumin dialysis (SPAD), 98
Sinusoidal obstructive disease, 39
Sinusoidal obstructive syndrome (SOS),
125–128, 130
clinical presentation and diagnosis
criteria, 127–129
physiopathology, 126
prevention, 129–131
risk factors, 127
treatment, 131, 132
delirium, 135
uid management, 132, 133
infection, 134, 135
liver dysfunction, 135
nutrition, 134
transfusion support, 133, 134
ventilation, 134
Sinusoidal occlusion, 34
Sleep disturbance, 72
Spheroid reservoir bio-articial liver
(SRBAL), 100
Spontaneous haemorrhagic syndrome, 44
Spontaneous liver allograft tolerance, 155
Sub-fulminant liver failure, 27
Systemic inammatory response syndrome
(SIRS), 5, 58, 60, 104
Systolic dysfunction, 116
T
Tacrolimus, 154
Terlipressine, 87
Tetrathiomolybdate, 48
Therapeutic plasma exchange (TPE), 98–100
Thoracocentesis, 133
Thrombotic microangiopathy (TMA), 128
Toxics, in acute liver failure, 38
Transcranial Doppler (TCD), 73
Transfusion-related acute hepatic injury
(TRAHI), 9
Transfusions, 9
Transjugular intrahepatic portosystemic shunt
(TIPS), 89
Treatment-associated liver injury, 7
DILI, 8–11
PNLAD, 7, 8
transfusions, 9
Tyrosinemia, 31
U
Urea cycle disorders, 32
Ursodeoxycholic acid (UA), 129
V
Valproic acid, 38
Vanishing bile duct syndrome, 138
Vascular and biliary complications, 148
Vascular cell adhesion molecule
(VCAM), 58–59
Vascular disorders, 39, 40
Vascular disorders/decrease in liver
perfusion, 34, 35
Vascular endothelial growth factor A
(VEGFA), 59
Vasoconstrictors, 87, 88
Veno-occlusive disease (VOD), 34, 132
Veno-occlussive or sinusoidal obstructive
disease, 39
Venous congestion, 6, 7
Viral infections, 32, 33, 36
Volatile anaesthetic agents, 37
W
Weight gain, 129
Wilson disease, 39, 42, 48, 57
Index
https://t.me/medicina_free